Table 4 Safety and Efficacy Outcomes
From: Comparison of anticoagulated versus non-anticoagulated patients with intra-aortic balloon pumps
Heparin group (n = 82) | Non-heparin group (n = 65) | Unadjusted p value | Adjusted* odds ratio (95% CIa) | Adjusted* p value | |
|---|---|---|---|---|---|
Main bleeding endpoint | 17 (20.7) | 13 (20.0) | 0.91 | 0.80 (0.31–2.09) | 0.65 |
Major access site bleeding | 2 (2.4) | 3 (4.6) | 0.47 | ||
Minor access site bleeding | 4 (4.9) | 5 (7.7) | 0.51 | ||
Major non-access site bleeding | 3 (3.7) | 3 (4.7) | 1 | ||
Minor non-access site bleeding | 7 (8.5) | 1 (1.5) | 0.08 | ||
Main thrombotic endpoint | 6 (7.3) | 5 (7.7) | 1 | 1.62 (0.42–6.3) | 0.42 |
Limb ischemia | 3 (3.7) | 1 (1.5) | 0.63 | ||
Device thrombosis | 1 (1.2) | 0 | N/A | ||
Venous thromboembolism | 1 (1.2) | 2 (3.1) | 0.58 | ||
Ischemic stroke | 1 (1.2) | 2 (3.1) | 0.58 |